Eris Lifesciences Limited — PPTs, 29-07-2026: Investor Presentation

Eris Lifesciences posted strong Q1 FY27 results. Consolidated revenue grew 13% YoY to ₹873 Cr, with PAT up 14.5% to ₹143 Cr. Domestic Branded Formulations (DBF) revenue rose 14.2% to ₹801 Cr, with 7 of 10 therapies showing double-digit growth. Key segments like Insulin surged 27.7%, and GLP-1 (Sundae) grew 165.5%, establishing Eris as an early leader in this new market, leading in prescriptions and units.

However, larger legacy segments like OAD and Cardiac are yet to regain full momentum. Strategic priorities include boosting these segments, entering the large ₹2,309 Cr Insulin Analogs market, and commercializing Eris Bionxt for supply control. Swiss Parenterals revenue grew 5% to ₹72 Cr, but EBITDA declined 19% as EU CAPA actions are underway, with clarity expected post Q2 FY27. EPS for the quarter stood at ₹10.27.